Protocol Ledger

NCT07011797 · Phase II · COMPLETED

A Study to Evaluate the Efficacy and Safety of CX11 Tablets in Overweight/Obese Participants

Interventional Phase II clinical trial protocol NCT07011797 sponsored by Corxel Pharmaceuticals in Endocrinology, Obesity, and Metabolic, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-06-17 Enrollment: 250 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT07011797
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)250 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07011797
Protocol FieldVerified Registry Value
NCT IdentifierNCT07011797
Consolidated Lead SponsorCorxel Pharmaceuticals
Therapeutic Condition CohortEndocrinology, Obesity, and Metabolic
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment250 participants (ACTUAL)
Registered Start Date2025-06-17
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07011797
Hospital Research SiteLocationSite Profile
Velocity Clinical Research (Cincinnati)Cincinnati, OHOpen Hospital Dossier ->
Velocity Clinical Research (Dallas)Dallas, TXOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI